Thornburg, Courtney D. http://orcid.org/0000-0002-5665-8958
Simmons, Dana H. http://orcid.org/0000-0003-4852-4703
von Drygalski, Annette http://orcid.org/0000-0002-9426-6322
Funding for this research was provided by:
Health Resources and Services Administration (H30MC24045)
Article History
Accepted: 7 July 2023
First Online: 25 July 2023
Declarations
:
: This work was supported by funding from the Health Resources and Services Administration (HRSA) H30MC24045.
: Courtney D. Thornburg has had institutional grant funding from BioMarin Pharmaceuticals. Courtney D. Thornburg has received honoraria for participating in scientific advisory panels, consulting, and speaking engagements for CSL Behring, HemaBiologics, Genentech, Pfizer, Sanofi Genzyme, and Spark Therapeutics. Courtney D. Thornburg has received fees for participation in data monitoring board from BlueBird Bio. Dana H. Simmons declares that she has no conflict of interest. Annette von Drygalski has received honoraria for participating in scientific advisory board panels, consulting, and speaking engagements for BioMarin, Regeneron, Pfizer, Bioverativ/Sanofi, CSL Behring, NovoNordisk, Spark Therapeutics, Genentech and UniQure. Annette von Drygalski is a co-founder and member of the Board of Directors of Hematherix LLC., a biotechnology company that is developing <sup>super</sup>FVa therapy for bleeding complications.
: None required, this work represents a review of available evidence.
: Not applicable, this work represents a review of available evidence.
: Not applicable.
: All authors listed made substantial contributions to this work according to ICMJE standards, drafted or revised the manuscript, approved the version to be published, and agree to be accountable for all aspects of the work.